



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)


PRODUCT INFORMATION



TP-060

Item No. 41127

CAS Registry No.: 2601393-20-6
Formal Name: 4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2,3-dihydro-2-[4-(1-hydroxy-1-methylethyl)phenyl]-1H-pyrrolo[3,4-c]pyridin-1-one
Synonym: T-036
MF: C₂₄H₂₀F₄N₂O₃
FW: 460.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TP-060 is supplied as a solid. A stock solution may be made by dissolving the TP-060 in the solvent of choice, which should be purged with an inert gas. TP-060 is slightly soluble (0.1-1 mg/ml) in acetonitrile and sparingly soluble (1-10 mg/ml) in DMSO.

Description

TP-060 is an inhibitor of UDP-glucose ceramide glucosyltransferase (IC₅₀ = 0.031 μM).¹ It is selective for UDP-glucose ceramide glucosyltransferase over human ether-a-go-go (hERG) at 10 μM but also inhibits serotonin receptors (5-HT; IC₅₀ = 0.31 μM). *In vivo*, TP-060 (30 mg/kg per day) decreases the cerebral cortex and serum levels of glucosylceramide and glucosylsphingosine in a Gba D409V transgenic mouse model of Gaucher disease.²

References

1. Tanaka, Y., Seto, M., Kakegawa, K., *et al.* Discovery of brain-penetrant glucosylceramide synthase inhibitors with a novel pharmacophore. *J. Med. Chem.* **65**(5), 4270-4290 (2022).
2. Fujii, T., Tanaka, Y., Oki, H., *et al.* A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease. *J. Neurochem.* **159**(3), 543-553 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/23/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM